Drug CEO Targeted by Clinton Is Criticized by Drug Lobby
- Turing "does not represent" values of drugmakers, group says
- Drugmaker acquired old medicine, raised price 50-fold
Drug Goes From $13.50 to $750 Overnight
This article is for subscribers only.
The top U.S. pharmaceutical lobby group said a drug company that has drawn criticism for a 50-fold price increase of a decades-old drug doesn’t match its companies’ values.
Turing Pharmaceuticals AG is not a member of the group, Pharmaceutical Research and Manufacturers of America, which represents drugmakers including Pfizer Inc., Merck & Co. and Amgen Inc. Yet Democratic presidential candidate Hillary Clinton used Turing as an example of what she called outrageous behavior by the industry, and issued a plan Tuesday to fight high drug prices.